Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells

Current Medicinal Chemistry

Volumn 23, Issue 15, 2016, Pages 1496-1512

  Corno, Cristina ^a   Gatti, Laura ^a   Lanzi, Cinzia ^a,c   Zaffaroni, Nadia ^a   Colombo, Diego ^b   Perego, Paola ^a,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SEMM European School of Molecular Medicine   (Italy)

Author keywords

Axl; Cancer; Drug resistance; Inhibitors.; Invasion; Receptor tyrosine kinases

Indexed keywords

AXL INHIBITOR; GROWTH ARREST SPECIFIC PROTEIN 6; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR TYROSINE KINASE AXL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

AGGRESSIVENESS; BIOLOGICAL FUNCTIONS; CANCER CELL; CELL SURVIVAL; HUMAN; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; REVIEW; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84974603298     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160405112954     Document Type: Review

References (110)

1. Hanahan, D. and Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-674.
2. Cassinelli, G.; Zuco, V.; Gatti, L.; Lanzi, C.; Zaffaroni, N.; Colombo, D.; Perego, P. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr. Med. Chem., 2013, 20, 1923-1945.
3. Cossa, G.; Gatti, L.; Cassinelli, G.; Lanzi, C.; Zaffaroni, N.; Perego, P. Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr. Pharm. Des., 2013, 19, 883-894.
4. Linger, R.M.; Keating, A.K.; Earp, H.S.; Graham, D.K. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res., 2008, 100, 35-83.
5. Robinson, D.R.; Wu, Y.M.; Lin, S.F. The protein tyrosine kinase family of the human genome. Oncogene, 2000, 19, 5548-5557.
6. Schlessinger, J. Receptor tyrosine kinases: legacy of the first two decades. Cold Spring Harb Perspect. Biol., 2014, 6, 10.1101/cshperspect.a008912.
7. Torti, D. and Trusolino, L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med., 2011, 3, 623-636.
8. Mahadevan, D.; Cooke, L.; Riley, C.; Swart, R.; Simons, B.; Della Croce, K.; Wisner, L.; Iorio, M.; Shakalya, K.; Garewal, H.; Nagle, R.; Bearss, D. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene, 2007, 26, 3909-3919.
9. O'Bryan, J.P.; Frye, R.A.; Cogswell, P.C.; Neubauer, A.; Kitch, B.; Prokop, C.; Espinosa, R. III.; Le Beau, M.M.; Earp, H.S.; Liu, E.T. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol., 1991, 11, 5016-5031.
10. Janssen, J.W.; Schulz, A.S.; Steenvoorden, A.C.; Schmidberger, M.; Strehl, S.; Ambros, P.F.; Bartram, C.R. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene, 1991, 6, 2113-2120.
11. Lemke, G. and Lu, Q. Macrophage regulation by Tyro 3 family receptors. Curr. Opin. Immunol., 2003, 15, 31-36.
12. Graham, D.K.; DeRyckere, D.; Davies, K.D.; Earp, H.S. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat. Rev. Cancer, 2014, 14, 769-785.
13. Liu, Y.W.; Yang, Q.F.; Zuo, P.Y.; Xiao, C.L.; Chen, X.L.; Liu, C.Y. Elevated serum levels of soluble Axl in acute coronary syndrome. Am. J. Med. Sci., 2015, 349, 124-129.
14. Batchu, S.N.; Xia, J.; Ko, K.A.; Doyley, M.M.; Abe, J.; Morrell, C.N.; Korshunov, V.A. Axl modulates immune activation of smooth muscle cells in vein graft remodeling. Am. J. Physiol. Heart Circ. Physiol., 2015, 309, H1048-58.
15. BioGPS datasets. Available from: www.biogps.org (Accessed September 24, 2015).
16. Angelillo-Scherrer, A.; de Frutos, P.; Aparicio, C.; Melis, E.; Savi, P.; Lupu, F.; Arnout, J.; Dewerchin, M.; Hoylaerts, M.; Herbert, J.; Collen, D.; Dahlback, B.; Carmeliet, P. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med., 2001, 7, 215-221.
17. Katagiri, M.; Hakeda, Y.; Chikazu, D.; Ogasawara, T.; Takato, T.; Kumegawa, M.; Nakamura, K.; Kawaguchi, H. Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts. J. Biol. Chem., 2001, 276, 7376-7382.
18. Lai, C.; Gore, M.; Lemke, G. Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene, 1994, 9, 2567-2578.
19. Lu, Q. and Lemke, G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science, 2001, 293, 306-311.
20. Mark, M.R.; Scadden, D.T.; Wang, Z.; Gu, Q.; Goddard, A.; Godowski, P.J. rse, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the brain. J. Biol. Chem., 1994, 269, 10720-10728.
21. Prasad, D.; Rothlin, C.V.; Burrola, P.; Burstyn-Cohen, T.; Lu, Q.; Garcia de Frutos, P.; Lemke, G. TAM receptor function in the retinal pigment epithelium. Mol. Cell. Neurosci., 2006, 33, 96-108.
22. Behrens, E.M.; Gadue, P.; Gong, S.Y.; Garrett, S.; Stein, P.L.; Cohen, P.L. The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity. Eur. J. Immunol., 2003, 33, 2160-2167.
23. Graham, D.K.; Dawson, T.L.; Mullaney, D.L.; Snodgrass, H.R.; Earp, H.S. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ., 1994, 5, 647-657.
24. GeneCards: The Human Gene Database. Available from: www.genecards.org (Accessed September 24, 2015).
25. Feneyrolles, C.; Spenlinhauer, A.; Guiet, L.; Fauvel, B.; Dayde-Cazals, B.; Warnault, P.; Cheve, G.; Yasri, A. Axl kinase as a key target for oncology: focus on small molecule inhibitors. Mol. Cancer. Ther., 2014, 13, 2141-2148.
26. Allen, M.P.; Zeng, C.; Schneider, K.; Xiong, X.; Meintzer, M.K.; Bellosta, P.; Basilico, C.; Varnum, B.; Heidenreich, K.A.; Wierman, M.E. Growth arrest-specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling promotes gonadotropin-releasing hormone neuronal survival via extracellular signal-regulated kinase (ERK) and Akt. Mol. Endocrinol., 1999, 13, 191-201.
27. Melaragno, M.G.; Wuthrich, D.A.; Poppa, V.; Gill, D.; Lindner, V.; Berk, B.C.; Corson, M.A. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ. Res., 1998, 83, 697-704.
28. Caraux, A.; Lu, Q.; Fernandez, N.; Riou, S.; Di Santo, J.P.; Raulet, D.H.; Lemke, G.; Roth, C. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat. Immunol., 2006, 7, 747-754.
29. Anderson, H.A.; Maylock, C.A.; Williams, J.A.; Paweletz, C.P.; Shu, H.; Shacter, E. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat. Immunol., 2003, 4, 87-91.
30. Zagorska, A.; Traves, P.G.; Lew, E.D.; Dransfield, I.; Lemke, G. Diversification of TAM receptor tyrosine kinase function. Nat. Immunol., 2014, 15, 920-928.
31. Braunger, J.; Schleithoff, L.; Schulz, A.S.; Kessler, H.; Lammers, R.; Ullrich, A.; Bartram, C.R.; Janssen, J.W. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene, 1997, 14, 2619-2631.
32. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103, 211-225.
33. Fridell, Y.W.; Jin, Y.; Quilliam, L.A.; Burchert, A.; McCloskey, P.; Spizz, G.; Varnum, B.; Der, C.; Liu, E.T. Differential activation of the Ras/extracellular-signalregulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol. Cell. Biol., 1996, 16, 135-145.
34. Hafizi, S.; Ibraimi, F.; Dahlback, B. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J., 2005, 19, 971-973.
35. Hafizi, S.; Alindri, F.; Karlsson, R.; Dahlback, B. Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem. Biophys. Res. Commun., 2002, 299, 793-800.
36. O'Bryan, J. P., Fridell, Y. W., Koski, R., Varnum, B., & Liu, E. T. The transforming receptor tyrosine kinase, axl, is post-translationally regulated by proteolytic cleavage. J. Biol. Chem., 1995, 270(2), 551-557.
37. Costa, M.; Bellosta, P.; Basilico, C. Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo. J. Cellular Physiol., 1996, 168(3), 737-744.
38. Ekman, C.; Stenhoff, J.; Dahlback, B. Gas6 is complexed to the soluble tyrosine kinase receptor axl in human blood. J. Thromb. Haemost., 2010, 8(4), 838-844.
39. Gustafsson, A.; Bostrom, A.K.; Ljungberg, B.; Axelson, H.; Dahlback, B. Gas6 and the receptor tyrosine kinase axl in clear cell renal cell carcinoma. PloS One, 2009, 4(10), e7575.
40. Johansson, G.; Peng, P.C.; Huang, P.Y.; Chien, H.F.; Hua, K.T.; Kuo, M.L. Soluble AXL: A possible circulating biomarker for neurofibromatosis type 1 related tumor burden. PloS One, 2014, 9(12), e115916.
41. Linger, R.M.; Cohen, R.A.; Cummings, C.T.; Sather, S.; Migdall-Wilson, J.; Middleton, D.H.; Lu, X.; Baron, A.E.; Franklin, W.A.; Merrick, D.T.; Jedlicka, P.; DeRyckere, D.; Heasley, L.E.; Graham, D.K. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene, 2013, 32, 3420-3431.
42. Li, M.; Lu, J.; Zhang, F.; Li, H.; Zhang, B.; Wu, X.; Tan, Z.; Zhang, L.; Gao, G.; Mu, J.; Shu, Y.; Bao, R.; Ding, Q.; Wu, W.; Dong, P.; Gu, J.; Liu, Y. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer Lett., 2014, 355, 201-209.
43. Liu, A.M.; Xu, M.Z.; Chen, J.; Poon, R.T.; Luk, J.M. Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin. Ther. Targets, 2010, 14, 855-868.
44. Xu, M.Z.; Chan, S.W.; Liu, A.M.; Wong, K.F.; Fan, S.T.; Chen, J.; Poon, R.T.; Zender, L.; Lowe, S.W.; Hong, W.; Luk, J.M. AXL receptor kinase is a mediator of YAPdependent oncogenic functions in hepatocellular carcinoma. Oncogene, 2011, 30, 1229-1240.
45. Xu, W.; Wei, Y.; Wu, S.; Wang, Y.; Wang, Z.; Sun, Y.; Cheng, S.Y.; Wu, J. Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. Cell Biosci., 2015, 5, 7-3701-5-7. eCollection 2015.
46. Mudduluru, G. and Allgayer, H. The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci. Rep., 2008, 28, 161-176.
47. Mudduluru, G.; Vajkoczy, P.; Allgayer, H. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol. Cancer Res., 2010, 8, 159-169.
48. Ott, M.; Litzenburger, U.M.; Sahm, F.; Rauschenbach, K.J.; Tudoran, R.; Hartmann, C.; Marquez, V.E.; von Deimling, A.; Wick, W.; Platten, M. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PLoS One, 2012, 7, e47663.
49. Vaughan, C.A.; Singh, S.; Windle, B.; Yeudall, W.A.; Frum, R.; Grossman, S.R.; Deb, S.P.; Deb, S. Gain-offunction activity of mutant p53 in lung cancer through upregulation of receptor protein tyrosine kinase Axl. Genes Cancer, 2012, 3, 491-502.
50. Demarchi, F.; Verardo, R.; Varnum, B.; Brancolini, C.; Schneider, C. Gas6 anti-apoptotic signaling requires NFkappa B activation. J. Biol. Chem., 2001, 276, 31738-31744.
51. Hasanbasic, I.; Cuerquis, J.; Varnum, B.; Blostein, M.D. Intracellular signaling pathways involved in Gas6-Axlmediated survival of endothelial cells. Am. J. Physiol. Heart Circ. Physiol., 2004, 287, H1207-H1213.
52. Lee, W.P.; Wen, Y.; Varnum, B.; Hung, M.C. Akt is required for Axl-Gas6 signaling to protect cells from E1Amediated apoptosis. Oncogene, 2002, 21, 329-336.
53. Huang, J.S.; Cho, C.Y.; Hong, C.C.; Yan, M.D.; Hsieh, M.C.; Lay, J.D.; Lai, G.M.; Cheng, A.L.; Chuang, S.E. Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism. Free Radic. Biol. Med., 2013, 65, 1246-1256.
54. Tsai, W.B.; Long, Y.; Park, J.R.; Chang, J.T.; Liu, H.; Rodriguez-Canales, J.; Savaraj, N.; Feun, L.G.; Davies, M.A.; Wistuba, I.I.; Kuo, M.T. Gas6/Axl is the sensor of arginineauxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene, 2016, 35(13), 1632-1642.
55. Li, Y.; Jia, L.; Ren, D.; Liu, C.; Gong, Y.; Wang, N.; Zhang, X.; Zhao, Y. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma. IUBMB Life, 2014, 66, 507-518.
56. Cichon, M.A.; Szentpetery, Z.; Caley, M.P.; Papadakis, E.S.; Mackenzie, I.C.; Brennan, C.H.; O'Toole, E.A. The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma. Oncogene, 2014, 33, 4185-4192.
57. Dunne, P.D.; McArt, D.G.; Blayney, J.K.; Kalimutho, M.; Greer, S.; Wang, T.; Srivastava, S.; Ong, C.W.; Arthur, K.; Loughrey, M.; Redmond, K.; Longley, D.B.; Salto-Tellez, M.; Johnston, P.G.; Van Schaeybroeck, S. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin. Cancer Res., 2014, 20, 164-175.
58. Alexander, S. and Friedl, P. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol. Med., 2012, 18, 13-26.
59. Radisky, D.C. Epithelial-mesenchymal transition. J. Cell. Sci., 2005, 118, 4325-4326.
60. Koorstra, J.B.; Karikari, C.A.; Feldmann, G.; Bisht, S.; Rojas, P.L.; Offerhaus, G.J.; Alvarez, H.; Maitra, A. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer. Biol. Ther., 2009, 8, 618-626.
61. Korshunov, V.A. Axl-dependent signalling: a clinical update. Clin. Sci. (Lond.), 2012, 122, 361-368.
62. Pierce, A.M. and Keating, A.K. TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system. Brain Res., 2014, 1542, 206-220.
63. Hutterer, M.; Knyazev, P.; Abate, A.; Reschke, M.; Maier, H.; Stefanova, N.; Knyazeva, T.; Barbieri, V.; Reindl, M.; Muigg, A.; Kostron, H.; Stockhammer, G.; Ullrich, A. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin. Cancer Res., 2008, 14, 130-138.
64. Cheng, P.; Phillips, E.; Kim, S.H.; Taylor, D.; Hielscher, T.; Puccio, L.; Hjelmeland, A.B.; Lichter, P.; Nakano, I.; Goidts, V. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell. Reports, 2015, 4, 899-913.
65. Tsai, N.M.; Chen, Y.L.; Lee, C.C.; Lin, P.C.; Cheng, Y.L.; Chang, W.L.; Lin, S.Z.; Harn, H.J. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J. Neurochem., 2006, 99, 1251-1262.
66. Yen, S.Y.; Chen, S.R.; Hsieh, J.; Li, Y.S.; Chuang, S.E.; Chuang, H.M.; Huang, M.H.; Lin, S.Z.; Harn, H.J.; Chiou, T.W. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion. Oncogene, 2016, 35(17), 2156-2165.
67. Macleod, K.; Mullen, P.; Sewell, J.; Rabiasz, G.; Lawrie, S.; Miller, E.; Smyth, J.F.; Langdon, S.P. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res., 2005, 65, 6789-6800.
68. Chen, P.X.; Li, Q.Y.; Yang, Z. Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann. Diagn. Pathol., 2013, 17, 425-429.
69. Rea, K.; Pinciroli, P.; Sensi, M.; Alciato, F.; Bisaro, B.; Lozneanu, L.; Raspagliesi, F.; Centritto, F.; Cabodi, S.; Defilippi, P.; Avanzi, G.C.; Canevari, S.; Tomassetti, A. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Oncotarget, 2015, 6(31), 30859-30875.
70. Sainaghi, P.P.; Castello, L.; Bergamasco, L.; Galletti, M.; Bellosta, P.; Avanzi, G.C. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J. Cell. Physiol., 2005, 204, 36-44.
71. Kim, K.C.; Choi, E.H.; Lee, C. Axl receptor tyrosine kinase is a novel target of apigenin for the inhibition of cell proliferation. Int. J. Mol. Med., 2014, 34, 592-598.
72. Zhou, S.; Liu, L.; Li, H.; Eilers, G.; Kuang, Y.; Shi, S.; Yan, Z.; Li, X.; Corson, J.M.; Meng, F.; Zhou, H.; Sheng, Q.; Fletcher, J.A.; Ou, W.B. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Br. J. Cancer, 2014, 110, 2479-2488.
73. Ou, W.B.; Hubert, C.; Corson, J.M.; Bueno, R.; Flynn, D.L.; Sugarbaker, D.J.; Fletcher, J.A. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia, 2011, 13, 12-22.
74. Pinato, D.J.; Mauri, F.A.; Lloyd, T.; Vaira, V.; Casadio, C.; Boldorini, R.L.; Sharma, R. The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br. J. Cancer, 2013, 108, 621-628.
75. Rettew, A.N.; Getty, P.J.; Greenfield, E.M. Receptor tyrosine kinases in osteosarcoma: not just the usual suspects. Adv. Exp. Med. Biol., 2014, 804, 47-66.
76. Han, J.; Tian, R.; Yong, B.; Luo, C.; Tan, P.; Shen, J.; Peng, T. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. Biochem. Biophys. Res. Commun., 2013, 435, 493-500.
77. Sensi, M.; Catani, M.; Castellano, G.; Nicolini, G.; Alciato, F.; Tragni, G.; De Santis, G.; Bersani, I.; Avanzi, G.; Tomassetti, A.; Canevari, S.; Anichini, A. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J. Invest. Dermatol., 2011, 131, 2448-2457.
78. Tworkoski, K.A.; Platt, J.T.; Bacchiocchi, A.; Bosenberg, M.; Boggon, T.J.; Stern, D.F. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res., 2013, 26, 527-541.
79. Dugo, M.; Nicolini, G.; Tragni, G.; Bersani, I.; Tomassetti, A.; Colonna, V.; Del Vecchio, M.; De Braud, F.; Canevari, S.; Anichini, A.; Sensi, M. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget, 2015, 6, 5118-5133.
80. Liu, L.; Greger, J.; Shi, H.; Liu, Y.; Greshock, J.; Annan, R.; Halsey, W.; Sathe, G.M.; Martin, A.M.; Gilmer, T.M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res., 2009, 69, 6871-6878.
81. Giles, K.M.; Kalinowski, F.C.; Candy, P.A.; Epis, M.R.; Zhang, P.M.; Redfern, A.D.; Stuart, L.M.; Goodall, G.J.; Leedman, P.J. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer. Ther., 2013, 12, 2541-2558.
82. Zhang, Z.; Lee, J.C.; Lin, L.; Olivas, V.; Au, V.; LaFramboise, T.; Abdel-Rahman, M.; Wang, X.; Levine, A.D.; Rho, J.K.; Choi, Y.J.; Choi, C.M.; Kim, S.W.; Jang, S.J.; Park, Y.S.; Kim, W.S.; Lee, D.H.; Lee, J.S.; Miller, V.A.; Arcila, M.; Ladanyi, M.; Moonsamy, P.; Sawyers, C.; Boggon, T.J.; Ma, P.C.; Costa, C.; Taron, M.; Rosell, R.; Halmos, B.; Bivona, T.G. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet., 2012, 44, 852-860.
83. Rho, J.K.; Choi, Y.J.; Kim, S.Y.; Kim, T.W.; Choi, E.K.; Yoon, S.J.; Park, B.M.; Park, E.; Bae, J.H.; Choi, C.M.; Lee, J.C. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res., 2014, 74, 253-262.
84. Suda, K.; Mizuuchi, H.; Sato, K.; Takemoto, T.; Iwasaki, T.; Mitsudomi, T. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. Int. J. Cancer, 2014, 135, 1002-1006.
85. Wilson, C.; Ye, X.; Pham, T.; Lin, E.; Chan, S.; McNamara, E.; Neve, R.M.; Belmont, L.; Koeppen, H.; Yauch, R.L.; Ashkenazi, A.; Settleman, J. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res., 2014, 74(20), 5878-5890.
86. Brand, T.M.; Iida, M.; Stein, A.P.; Corrigan, K.L.; Braverman, C.M.; Luthar, N.; Toulany, M.; Gill, P.S.; Salgia, R.; Kimple, R.J.; Wheeler, D.L. AXL mediates resistance to cetuximab therapy. Cancer Res., 2014, 74, 5152-5164.
87. Elkabets, M.; Pazarentzos, E.; Juric, D.; Sheng, Q.; Pelossof, R.A.; Brook, S.; Benzaken, A.O.; Rodon, J.; Morse, N.; Yan, J.J.; Liu, M.; Das, R.; Chen, Y.; Tam, A.; Wang, H.; Liang, J.; Gurski, J.M.; Kerr, D.A.; Rosell, R.; Teixido, C.; Huang, A.; Ghossein, R.A.; Rosen, N.; Bivona, T.G.; Scaltriti, M.; Baselga, J. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell, 2015, 27, 533-546.
88. Kim, K.C.; Lee, C. Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells. Korean J. Physiol. Pharmacol., 2014, 18, 61-66.
89. Hong, C.C.; Lay, J.D.; Huang, J.S.; Cheng, A.L.; Tang, J.L.; Lin, M.T.; Lai, G.M.; Chuang, S.E. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett., 2008, 268, 314-324.
90. Yoshida, T.; Zhang, G.; Smith, M.A.; Lopez, A.S.; Bai, Y.; Li, J.; Fang, B.; Koomen, J.; Rawal, B.; Fisher, K.J.; Chen, A.Y.; Kitano, M.; Morita, Y.; Yamaguchi, H.; Shibata, K.; Okabe, T.; Okamoto, I.; Nakagawa, K.; Haura, E.B. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin. Cancer Res., 2014, 20, 4059-4074.
91. Bae, S.Y.; Hong, J.Y.; Lee, H.J.; Park, H.J.; Lee, S.K. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer. Oncotarget, 2015, 6, 10146-10160.
92. Hari, S.B.; Merritt, E.A.; Maly, D.J. Sequence determinants of a specific inactive protein kinase conformation. Chem. Biol., 2013, 20, 806-815.
93. Liu, Y. and Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol., 2006, 2, 358-364.
94. Suarez, R.M.; Chevot, F.; Cavagnino, A.; Saettel, N.; Radvanyi, F.; Piguel, S.; Bernard-Pierrot, I.; Stoven, V.; Legraverend, M. Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. Eur. J. Med. Chem., 2013, 61, 2-25.
95. Davis, M.I.; Hunt, J.P.; Herrgard, S.; Ciceri, P.; Wodicka, L.M.; Pallares, G.; Hocker, M.; Treiber, D.K.; Zarrinkar, P.P. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 2011, 29, 1046-1051.
96. U.S. National Institute of Health. Available from: https://clinicaltrials.gov (Accessed November 15, 2015)
97. Cortes, J.E.; Kim, D.W.; Kantarjian, H.M.; Brummendorf, T.H.; Dyagil, I.; Griskevicius, L.; Malhotra, H.; Powell, C.; Gogat, K.; Countouriotis, A.M.; Gambacorti-Passerini, C. Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia: results from the BELA trial. J. Clin. Oncol., 2012, 30, 3486-3492.
98. Vouri, M.; An, Q.; Birt, M.; Pilkington, G.J.; Hafizi, S. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells. Oncotarget , 2015, 6, 16183-16197.
99. Zhao, H.; Luoto, K.R.; Meng, A.X.; Bristow, R.G. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother. Oncol., 2011, 101, 59-65.
100. Mita, M.; Gordon, M.; Rosen, L.; Kapoor, N.; Choy, G.; Redkar, S.; Taverna, P.; Oganesian, A.; Sahai, A.; Azab, M.; Bristow, R.; Tolcher, A.W. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother. Pharmacol., 2014, 74, 195-204.
101. Sinha, S.; Boysen, J.; Nelson, M.; Secreto, C.; Warner, S.L.; Bearss, D.J.; Lesnick, C.; Shanafelt, T.D.; Kay, N.E.; Ghosh, A.K. Targeted Axl inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors. Clin. Cancer Res., 2015, 21, 2115-2126.
102. Wu, X.; Liu, X.; Koul, S.; Lee, C.Y.; Zhang, Z.; Halmos, B. AXL kinase as a novel target for cancer therapy. Oncotarget, 2014, 5, 9546-9563.
103. Zhang, Y.X.; Knyazev, P.G.; Cheburkin, Y.V.; Sharma, K.; Knyazev, Y.P.; Orfi, L.; Szabadkai, I.; Daub, H.; Keri, G.; Ullrich, A. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res., 2008, 68, 1905-1915.
104. Messoussi, A.; Peyronnet, L.; Feneyrolles, C.; Cheve, G.; Bougrin, K.; Yasri, A. Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors. Molecules, 2014, 19, 16223-16239.
105. Paolino, M.; Choidas, A.; Wallner, S.; Pranjic, B.; Uribesalgo, I.; Loeser, S.; Jamieson, A.M.; Langdon, W.Y.; Ikeda, F.; Fededa, J.P.; Cronin, S.J.; Nitsch, R.; Schultz-Fademrecht, C.; Eickhoff, J.; Menninger, S.; Unger, A.; Torka, R.; Gruber, T.; Hinterleitner, R.; Baier, G.; Wolf, D.; Ullrich, A.; Klebl, B.M.; Penninger, J.M. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature, 2014, 507, 508-512.
106. Traore, T.; Cavagnino, A.; Saettel, N.; Radvanyi, F.; Piguel, S.; Bernard-Pierrot, I.; Stoven, V.; Legraverend, M. New aminopyrimidine derivatives as inhibitors of the TAM family. Eur. J. Med. Chem., 2013, 70, 789-801.
107. Liu, J.; Yang, C.; Simpson, C.; Deryckere, D.; Van Deusen, A.; Miley, M.J.; Kireev, D.; Norris-Drouin, J.; Sather, S.; Hunter, D.; Korboukh, V.K.; Patel, H.S.; Janzen, W.P.; Machius, M.; Johnson, G.L.; Earp, H.S.; Graham, D.K.; Frye, S.V.; Wang, X. Discovery of novel small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia. ACS Med. Chem. Lett., 2012, 3, 129-134.
108. Da, C.; Stashko, M.; Jayakody, C.; Wang, X.; Janzen, W.; Frye, S.; Kireev, D. Discovery of Mer kinase inhibitors by virtual screening using Structural Protein-Ligand Interaction Fingerprints. Bioorg. Med. Chem., 2015, 23, 1096-1101.
109. Christoph, S.; Deryckere, D.; Schlegel, J.; Frazer, J.K.; Batchelor, L.A.; Trakhimets, A.Y.; Sather, S.; Hunter, D.M.; Cummings, C.T.; Liu, J.; Yang, C.; Kireev, D.; Simpson, C.; Norris-Drouin, J.; Hull-Ryde, E.A.; Janzen, W.P.; Johnson, G.L.; Wang, X.; Frye, S.V.; Earp, H.S.,3rd; Graham, D.K. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol. Cancer. Ther., 2013, 12, 2367-2377.
110. Janning, M.; Ben-Batalla, I.; Loges, S. Axl inhibiton: a potential road to a novel acute myeloid leukemia therapy? Expert Rev. Hematol., 2015, 8(2), 135-138.